116 related articles for article (PubMed ID: 38640931)
1. Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy.
Yang Y; Wang Y; Zeng F; Chen Y; Chen Z; Yan F
Cell Rep Med; 2024 May; 5(5):101512. PubMed ID: 38640931
[TBL] [Abstract][Full Text] [Related]
2. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death.
Guo Y; Qian R; Li Z; Lv T; Yang C; Li W; Pan T; Hou X; Wang Z
Life Sci; 2024 Jul; 348():122687. PubMed ID: 38718856
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
[TBL] [Abstract][Full Text] [Related]
5. Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy.
Chen Y; Du M; Yuan Z; Chen Z; Yan F
Nat Commun; 2022 Aug; 13(1):4468. PubMed ID: 35918309
[TBL] [Abstract][Full Text] [Related]
6. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.
Wang H; Najibi AJ; Sobral MC; Seo BR; Lee JY; Wu D; Li AW; Verbeke CS; Mooney DJ
Nat Commun; 2020 Nov; 11(1):5696. PubMed ID: 33173046
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin.
Jang Y; Cho YS; Kim A; Zhou X; Kim Y; Wan Z; Moon JJ; Park H
ACS Appl Mater Interfaces; 2024 Apr; 16(14):17129-17144. PubMed ID: 38533538
[TBL] [Abstract][Full Text] [Related]
8. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
10. Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy.
Wang Y; Wang Z; Chen B; Yin Q; Pan M; Xia H; Zhang B; Yan Y; Jiang Z; Zhang Q; Wang Y
Nano Lett; 2021 May; 21(10):4371-4380. PubMed ID: 33984236
[TBL] [Abstract][Full Text] [Related]
11. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
[TBL] [Abstract][Full Text] [Related]
12. Combining Mechanical High-Intensity Focused Ultrasound Ablation with Chemotherapy for Augmentation of Anticancer Immune Responses.
Li C; Lu Y; Cheng L; Zhang X; Yue J; Liu J
Mol Pharm; 2021 May; 18(5):2091-2103. PubMed ID: 33886331
[TBL] [Abstract][Full Text] [Related]
13. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Immunogenic Cell Death and Antigen Presentation
He T; Wang L; Gou S; Lu L; Liu G; Wang K; Yang Y; Duan Q; Geng W; Zhao P; Luo Z; Cai K
ACS Nano; 2023 Jun; 17(11):9953-9971. PubMed ID: 37212750
[TBL] [Abstract][Full Text] [Related]
15. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS; Arlauckas SP; Kohler RH; Trefny MP; Garren S; Piot C; Engblom C; Pfirschke C; Siwicki M; Gungabeesoon J; Freeman GJ; Warren SE; Ong S; Browning E; Twitty CG; Pierce RH; Le MH; Algazi AP; Daud AI; Pai SI; Zippelius A; Weissleder R; Pittet MJ
Immunity; 2018 Dec; 49(6):1148-1161.e7. PubMed ID: 30552023
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
18. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S
J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039
[TBL] [Abstract][Full Text] [Related]
19. DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy.
Nie C; Ye J; Jiang JH; Chu X
J Colloid Interface Sci; 2024 Aug; 667():1-11. PubMed ID: 38615618
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.
Kong M; Tang J; Qiao Q; Wu T; Qi Y; Tan S; Gao X; Zhang Z
Theranostics; 2017; 7(13):3276-3292. PubMed ID: 28900509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
